CD274 and neoplasm: By employing an shRNA-mediated PD-1-silencing approach intrinsic to CAR T cells, they achieved a significant reduction in PD-1 on the T cell surface, which in turn significantly enhanced CAR T cell cytokine production and cytotoxicity against PD-L1-expressing tumour cells in vitro.